Assembly Bio Posts $20.3M Q3 Loss, Secures $75M Gilead Fee and 2029 Runway
ASMB is trading near its 52-week low of $19.2 (5.2% above the low).
Summary
Assembly Bio reported a Q3 2026 net loss of $20.3 million, or $0.93 per share, versus $9.2 million a year earlier, as R&D spending rose to $20.2 million on multiple ABI-6250 study starts. Revenue from the Gilead collaboration fell to $3.0 million from $10.8 million, driven by an $11.3 million reduction in the HPI license transaction price tied to expected profit-share reimbursements. The balance sheet is the story: $314.3 million in cash and securities at September 30, plus the first $75 million collaboration extension fee received from Gilead in November, funds operations into 2029. That follows the September 8 exercise of the 40% U.S. profit-share option on the HSV helicase-primase program and the October 5 positive Phase 1a ABI-6250 data. Dosing has begun in the Phase 2 HDV study, and the FDA cleared the path for a Phase 2 cholestatic liver disease study expected to start in Q1 2027. Gilead is slated to begin a Phase 2 study of GS-1179 in recurrent genital herpes by year-end 2026.
At the time of this announcement, ASMB was trading at $20.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $410.9M. The 52-week trading range was $19.20 to $39.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.